In conclusion, we comprehensively evaluated exonic genetic variations for association with ALL susceptibility and identified novel coding risk variants at the CDKN2A–CDKN2B locus that may directly affect tumour suppressor functions and potentiate leukaemic transformation. The gene discussed is CDKN2A; the disease is acute lymphoblastic leukemia.